Rosiglitazone induces caveolin-1 by PPARγ-dependent and PPRE-independent mechanisms: The role of EGF receptor signaling and its effect on cancer cell drug resistance

Anticancer Research

Volumn 28, Issue 2 A, 2008, Pages 895-906

  Tencer, Lilach ^a   Burgermeister, Elke ^b   Ebert, Matthias P ^b   Liscovitch, Mordechai ^a  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Cancer; Caveolin 1; EGF receptor; MAP kinase signaling; PPAR ; Rosiglitazone

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 4 (3 CHLOROANILINO) 6,7 DIMETHOXYQUINAZOLINE; 4 (4 FLUOROPHENYL) 2 (4 HYDROXYPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; 4 AMINO 7 TERT BUTYL 5 (4 CHLOROPHENYL)PYRAZOLO[3,4 D]PYRIMIDINE; ACETYLCYSTEINE; CAVEOLIN 1; CIGLITAZONE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; HYDROGEN PEROXIDE; MESSENGER RNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; REACTIVE OXYGEN METABOLITE; ROSIGLITAZONE; SUPEROXIDE; TROGLITAZONE;

ARTICLE; CANCER CELL; CANCER RESISTANCE; CELL STRAIN HT29; CELL SURVIVAL; CONTROLLED STUDY; DNA RESPONSIVE ELEMENT; DRUG MECHANISM; FLOW CYTOMETRY; GENE EXPRESSION; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN INDUCTION; PROTEIN PHOSPHORYLATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; UPREGULATION; WESTERN BLOTTING;

CAVEOLIN 1; CELL SURVIVAL; DRUG RESISTANCE, NEOPLASM; EPIDERMAL GROWTH FACTOR; HT29 CELLS; HUMANS; PPAR GAMMA; REACTIVE OXYGEN SPECIES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RNA, MESSENGER; SIGNAL TRANSDUCTION; SUPEROXIDES; THIAZOLIDINEDIONES;

EID: 42549124085     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (94)

1. Rosen ED and Spiegelman BM: PPARγ: a nuclear regulator of metabolism, differentiation, and cell growth. J Biol Chem 276: 37731-37734, 2001.
2. Berger J and Moller DE: The mechanisms of action of PPARs. Annu Rev Med 53: 409-443, 2002.
3. Kliewer SA, Lenhard JM, Willson TM, Patel I, Morris DC and Lehmann JM; A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor γ and promotes adipocyte differentiation. Cell 83: 813-819, 1995.
4. Lehmann JM, Moore LB, Smith-Oliver TA, Wilkison WO, Willson TM and Kliewer SA: An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor γ (PPAR γ). J Biol Chem 270: 12953-12956, 1995.
5. Kendall DM: Thiazolidinediones: the case for early use. Diabetes Care 29: 154-157, 2006.
6. Kliewer SA and Willson TM: The nuclear receptor PPARγ - bigger than fat. Curr Opin Genet Dev 8: 576-581, 1998.
7. Fajas L, Debril MB and Auwerx J: Peroxisome proliferator-activated receptor-γ: from adipogenesis to carcinogenesis. J Mol Endocrinol 27: 1-9, 2001.
8. Tontonoz P, Singer S, Forman BM, Sarraf P, Fletcher JA, Fletcher CD, Brun RP, Mueller E, Altiok S, Oppenheim H, Evans RM and Spiegelman BM: Terminal differentiation of human liposarcoma cells induced by ligands for peroxisome proliferator-activated receptor γ and the retinoid X receptor. Proc Natl Acad Sci USA 94: 237-241, 1997.
9. Mueller E, Sarraf P, Tontonoz P, Evans RM, Martin KJ, Zhang M, Fletcher C, Singer S and Spiegelman BM, Terminal differentiation of human breast cancer through PPAR γ. Mol Cell 1: 465-470, 1998.
10. Kitamura S, Miyazaki Y, Shinomura Y, Kondo S, Kanayama S and Matsuzawa Y: Peroxisome proliferator-activated receptor γ induces growth arrest and differentiation markers of human colon cancer cells. Jpn J Cancer Res 90: 75-80, 1999.
11. Konopleva M, Elstner E, McQueen TJ, Tsao T, Sudarikov A, Hu W, Schober WD, Wang RY, Chism D, Kornblau SM, Younes A, Collins SJ, Koeffler HP and Andreeff M: Peroxisome proliferator-activated receptor y and retinoid X receptor ligands are potent inducers of differentiation and apoptosis in leukemias. Mol Cancer Ther 3: 1249-1262, 2004.
12. Demetri GD, Fletcher CD, Mueller E, Sarraf P, Naujoks R, Campbell N, Spiegelman BM and Singer S: Induction of solid tumor differentiation by the peroxisome proliferator-activated receptor-γ ligand troglitazone in patients with liposarcoma. Proc Natl Acad Sci USA 96: 3951-3956, 1999.
13. Mueller E, Smith M, Sarraf P, Kroll T, Aiyer A, Kaufman DS, Oh W, Demetri G, Figg WD, Zhou XP, Eng C, Spiegelman BM and Kantoff PW: Effects of ligand activation of peroxisome proliferator-activated receptor γ in human prostate cancer. Proc Natl Acad Sci USA 97: 10990-10995, 2000.
14. Gouni-Berthold I, Berthold HK, Weber AA, Ko Y, Seul C, Vetter H and Sachinidis A: Troglitazone and rosiglitazone induce apoptosis of vascular smooth muscle cells through an extracellular signal-regulated kinase-independent pathway. Naunyn Schmiedebergs Arch Pharmacol 363: 215-221, 2001.
15. Takeda K, Ichiki T, Tokunou T, Iino N and Takeshita A: 15-Deoxy-delta 12,14-prostaglandin J2 and thiazolidinediones activate the MEK/ERK pathway through phosphatidylinositol 3-kinase in vascular smooth muscle cells. J Biol Chem 276: 48950-48955, 2001.
16. Chaffer CL, Thomas DM, Thompson EW and Williams ED: PPARγ- independent induction of growth arrest and apoptosis in prostate and bladder carcinoma. BMC Cancer 6: 53, 2006.
17. Burgermeister E, Tencer L and Liscovitch M: Peroxisome proliferator-activated receptor-γ up-regulates caveolin-1 and caveolin-2 expression in human carcinoma cells. Oncogene 22: 3888-3900, 2003.
18. Schlegel A and Lisanti MP: The caveolin triad: caveolae biogenesis, cholesterol trafficking, and signal transduction. Cytokine Growth Factor Rev 12: 41-51, 2001.
19. Smart EJ, Graf GA, McNiven MA, Sessa WC, Engelman JA, Scherer PE, Okamoto T and Lisanti MP: Caveolins, liquid-ordered domains, and signal transduction. Mol Cell Biol 19: 7289-7304, 1999.
20. Brown DA and London E: Structure and function of sphingolipid- and cholesterol-rich membrane rafts. J Biol Chem 275: 17221-17224, 2000.
21. Scherer PE, Lisanti MP, Baldini G, Sargiacomo M, Mastick CC and Lodish HF: Induction of caveolin during adipogenesis and association of GLUT4 with caveolin-rich vesicles. J Cell Biol 127: 1233-1243, 1994.
22. Scherer PE, Lewis RY, Volonte D, Engelman JA, Galbiati F, Couet J, Kohtz DS, van Donselaar E, Peters P and Lisanti MP: Cell-type and tissue-specific expression of caveolin-2. Caveolins 1 and 2 co-localize and form a stable hetero-oligomeric complex in vivo. J Biol Chem 272: 29337-29346, 1997.
23. Galbiati F, Volonte D, Gil O, Zanazzi G, Salzer JL, Sargiacomo M, Scherer PE, Engelman JA, Schlegel A, Parenti M, Okamoto T and Lisanti MP, Expression of caveolin-1 and -2 in differentiating PC12 cells and dorsal root ganglion neurons: caveolin-2 is up-regulated in response to cell injury. Proc Natl Acad Sci USA 95: 10257-10262, 1998.
24. Campbell L, Hollins AJ, Al-Eid A, Newman GR, von Ruhland C and Gumbleton M: Caveolin-1 expression and caveolae biogenesis during cell transdifferentiation in lung alveolar epithelial primary cultures. Biochem Biophys Res Commun 262: 744-751, 1999.
25. Matveev S, van der Westhuyzen DR and Smart EJ: Co-expression of scavenger receptor-BI and caveolin-1 is associated with enhanced selective cholesteryl ester uptake in THP-1 macrophages. J Lipid Res 40: 1647-1654, 1999.
26. Liu J, Wang XB, Park DS and Lisanti MP, Caveolin-1 expression enhances endothelial capillary tubule formation. J Biol Chem 277: 10661-10668, 2002.
27. Liscovitch M, Burgermeister E, Jain N, Ravid D, Shatz M and Tencer L: Caveolin and cancer: a complex relationship. In: Membrane Microdomains Signaling. Lipid Rafts in Biology and Medicine. (Ed. MP Mattson), Human press, Totowa, New Jersey, pp. 161-190, 2005.
28. Williams TM and Lisanti MP: Caveolin-1 in oncogenic transformation, cancer, and metastasis. Am J Physiol Cell Physiol 288: C494-C506, 2005.
29. Williams TM, Cheung MW, Park DS, Razani B, Cohen AW, Muller WJ, Di Vizio D, Chopra NG, Pestell RG and Lisanti MP: Loss of caveolin-1 gene expression accelerates the development of dysplastic mammary lesions in tumor-prone transgenic mice. Mol Biol Cell 14: 1027-1042, 2003.
30. Capozza F, Williams TM, Schubert W, McClain S, Bouzahzah B, Sotgia F and Lisanti MP: Absence of caveolin-1 sensitizes mouse skin to carcinogen-induced epidermal hyperplasia and tumor formation. Am J Pathol 162: 2029-2039, 2003.
31. Nasu Y, Timme TL, Yang G, Bangma CH, Li L, Ren C, Park SH, DeLeon M, Wang J and Thompson TC: Suppression of caveolin expression induces androgen sensitivity in metastatic androgen-insensitive mouse prostate cancer cells. Nat Med 4: 1062-1064, 1998.
32. Timme TL, Goltsov A, Tahir S, Li L, Wang J, Ren C, Johnston RN and Thompson TC: Caveolin-1 is regulated by c-myc and suppresses c-myc-induced apoptosis. Oncogene 19: 3256-3265, 2000.
33. Tahir SA, Yang G, Ebara S, Timme TL, Satoh T, Li L, Goltsov A, Ittmann M, Morrisett JD and Thompson TC: Secreted caveolin-1 stimulates cell survival/clonal growth and contributes to metastasis in androgen-insensitive prostate cancer. Cancer Res 61: 3882-3885, 2001.
34. Fiucci G, Ravid D, Reich R and Liscovitch M: Caveolin-1 inhibits anchorage-independent growth, anoikis and invasiveness in MCF-7 human breast cancer cells. Oncogene 21: 2365-2375, 2002.
35. Ravid D, Maor S, Werner H and Liscovitch M: Caveolin-1 inhibits cell detachment-induced p53 activation and anoikis by upregulation of insulin-like growth factor-I receptors and signaling. Oncogene 24: 1338-1347, 2005.
36. Glait C, Tencer L, Ravid D, Sarfstein R, Liscovitch M and Werner H: Caveolin-1 up-regulates IGF-I receptor gene transcription in breast cancer cells via Sp1- and p53-dependent pathways. Exp Cell Res 312: 3899-3908, 2006.
37. Williams TM, Hassan GS, Li J, Cohen AW, Medina F, Frank PG, Pestell RG, Di Vizio D, Loda M and Lisanti MP: Caveolin-1 promotes tumor progression in an autochthonous mouse model of prostate cancer: genetic ablation of Cav-1 delays advanced prostate tumor development in tramp mice. J Biol Chem 280: 25134-25145, 2005.
38. Yu S, Matsusue K, Kashireddy P, Cao WQ, Yeldandi V, Yeldandi AV, Rao MS, Gonzalez FJ and Reddy JK: Adipocyte-specific gene expression and adipogenic steatosis in the mouse liver due to peroxisome proliferator-activated receptor γ1 (PPARγ1) overexpression. J Biol Chem 278: 498-505, 2003.
39. Lemay DG and Hwang DH: Genome-wide identification of peroxisome proliferator response elements using integrated computational genomics. J Lipid Res 47: 1583-1587, 2006.
40. Gardner OS, Dewar BJ, Earp HS, Samet JM and Graves LM: Dependence of peroxisome proliferator-activated receptor ligand-induced mitogen-activated protein kinase signaling on epidermal growth factor receptor transactivation. J Biol Chem 278: 46261-46269, 2003.
41. Hansen MB, Nielsen SE and Berg K: Re-examination and further development of a precise and rapid dye method for measuring cell growth/cell kill. J Immunol Methods 119: 203-210, 1989.
42. Ichiki T, Tokunou T, Fukuyama K, Iino N, Masuda S and Takeshita A: 15-Deoxy-delta12,14-prostaglandin J2 and thiazolidinediones transactivate epidermal growth factor and platelet-derived growth factor receptors in vascular smooth muscle cells. Biochem Biophys Res Commun 323: 402-408, 2004.
43. Ohtsu H, Dempsey PJ, Frank GD, Brailoiu E, Higuchi S, Suzuki H, Nakashima H, Eguchi K and Eguchi S: ADAM17 mediates epidermal growth factor receptor transactivation and vascular smooth muscle cell hypertrophy induced by angiotensin II. Arterioscler Thromb Vasc Biol 26: e133-e137, 2006.
44. Shishido S, Koga H, Harada M, Kumemura H, Hanada S, Taniguchi E, Kumashiro R, Ohira H, Sato Y, Namba M, Ueno T and Sata M: Hydrogen peroxide overproduction in megamitochondria of troglitazone-treated human hepatocytes. Hepatology 37: 136-147, 2003.
45. Fernandes DC, Wosniak J Jr, Pescatore LA, Bertoline MA, Liberman M, Laurindo FR and Santos CX: Analysis of DHE-derived oxidation products by HPLC in the assessment of superoxide production and NADPH oxidase activity in vascular systems. Am J Physiol Cell Physiol 292: C413-C422, 2007.
46. Al-Shabrawey M, Bartoli M, El-Remessy AB, Platt DH, Matragoon S, Behzadian MA, Caldwell RW and Caldwell RB: Inhibition of NAD(P)H oxidase activity blocks vascular endothelial growth factor overexpression and neovascularization during ischemic retinopathy. Am J Pathol 167: 599-607, 2005.
47. Singh KK: Mitochondria damage checkpoint, aging, and cancer. Ann NY Acad Sci 1067: 182-190, 2006.
48. Machida K and Tanaka T: Farnesol-induced generation of reactive oxygen species dependent on mitochondrial transmembrane potential hyperpolarization mediated by F(0)F(1)-ATPase in yeast. FEBS Lett 462: 108-112, 1999.
49. 2+- and redox-dependent production of nitric oxide. J Immunol 171: 5188-5197, 2003.
50. Lin Y, Berg AH, Iyengar P, Lam TK, Giacca A, Combs TP, Rajala MW, Du X, Rollman B, Li W, Hawkins M, Barzilai N, Rhodes CJ, Fantus IG, Brownlee M and Scherer PE: The hyperglycemia-induced inflammatory response in adipocytes: the role of reactive oxygen species. J Biol Chem 280: 4617-4626, 2005.
51. Clement MV, Hirpara JL and Pervaiz S: Decrease in intracellular superoxide sensitizes Bcl-2-overexpressing tumor cells to receptor and drug-induced apoptosis independent of the mitochondria. Cell Death Differ 10: 1273-1285, 2003.
52. Normanno N, De Luca A, Bianco C, Strizzi L, Mancino M, Maiello MR, Carotenuto A, De Feo G, Caponigro F and Salomon DS: Epidermal growth factor receptor (EGFR) signaling in cancer. Gene 366: 2-16, 2006.
53. Ravid D, Maor S, Werner H and Liscovitch M: Caveolin-1 inhibits anoikis and promotes survival signaling in cancer cells. Adv Enzyme Regul 46: 163-175, 2006.
54. Gewirtz DA: A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. Biochem Pharmacol 57: 727-741, 1999.
55. Llaverias G, Vazquez-Carrera M, Sanchez RM, Noe V, Ciudad CJ, Laguna JC and Alegret M: Rosiglitazone upregulates caveolin-1 expression in THP-1 cells through a PPAR-dependent mechanism. J Lipid Res 45: 2015-2024, 2004.
56. Chintharlapalli S, Smith R, 3rd, Samudio I, Zhang W and Safe S: 1,1-Bis(3′-indolyl)-1-(p-substituted phenyl)methanes induce peroxisome proliferator-activated receptor γ-mediated growth inhibition, transactivation, and differentiation markers in colon cancer cells. Cancer Res 64: 5994-6001, 2004.
57. Prenzel N, Zwick E, Daub H, Leserer M, Abraham R, Wallasch C and Ullrich A: EGF receptor transactivation by G-protein-coupled receptors requires metalloproteinase cleavage of proHB-EGF. Nature 402: 884-888, 1999.
58. Ohtsu H, Dempsey PJ and Eguchi S: ADAMs as mediators of EGF receptor transactivation by G protein-coupled receptors. Am J Physiol Cell Physiol 291: C1-C10, 2006.
59. Feinstein DL, Spagnolo A, Akar C, Weinberg G, Murphy P, Gavrilyuk V and Dello Russo C: Receptor-independent actions of PPAR thiazolidinedione agonists: is mitochondrial function the key? Biochem Pharmacol 70: 177-188, 2005.
60. Tice DA, Biscardi JS, Nickles AL and Parsons SJ: Mechanism of biological synergy between cellular Src and epidermal growth factor receptor. Proc Natl Acad Sci USA 96: 1415-1420, 1999.
61. Moro L, Dolce L, Cabodi S, Bergatto E, Erba EB, Smeriglio M, Turco E, Retta SF, Giuffrida MG, Venturino M, Godovac-Zimmermann J, Conti A, Schaefer E, Beguinot L, Tacchetti C, Gaggini P, Silengo L, Tarone G and Defilippi P: Integrin-induced epidermal growth factor (EGF) receptor activation requires c-Src and p130Cas and leads to phosphorylation of specific EGF receptor tyrosines. J Biol Chem 277: 9405-9414, 2002.
62. Tirmenstein MA, Hu CX, Gales TL, Maleeff BE, Narayanan PK, Kurali E, Hart TK, Thomas HC and Schwartz LW: Effects of troglitazone on HepG2 viability and mitochondrial function. Toxicol Sci 69: 131-138, 2002.
63. Dello Russo C, Gavrilyuk V, Weinberg G, Almeida A, Bolanos JP, Palmer J, Pelligrino D, Galea E and Feinstein DL: Peroxisome proliferator-activated receptor γ thiazolidinedione agonists increase glucose metabolism in astrocytes. J Biol Chem 278: 5828-5836, 2003.
64. Perez-Ortiz JM, Tranque P, Vaquero CF, Domingo B, Molina F, Calvo S, Jordan J, Cena V and Llopis J: Glitazones differentially regulate primary astrocyte and glioma cell survival. Involvement of reactive oxygen species and peroxisome proliferator-activated receptor-γ. J Biol Chem 279: 8976-8985, 2004.
65. Couet J, Sargiacomo M and Lisanti MP: Interaction of a receptor tyrosine kinase, EGF-R, with caveolins. Caveolin binding negatively regulates tyrosine and serine/threonine kinase activities. J Biol Chem 272: 30429-30438, 1997.
66. Mineo C, Gill GN and Anderson RG: Regulated migration of epidermal growth factor receptor from caveolae. J Biol Chem 274: 30636-30643, 1999.
67. Park WY, Park JS, Cho KA, Kim DI, Ko YG, Seo JS and Park SC: Up-regulation of caveolin attenuates epidermal growth factor signaling in senescent cells. J Biol Chem 275: 20847-20852, 2000.
68. Lu Z, Ghosh S, Wang Z and Hunter T: Downregulation of caveolin-1 function by EGF leads to the loss of E-cadherin, increased transcriptional activity of beta-catenin, and enhanced tumor cell invasion. Cancer Cell 4: 499-515, 2003.
69. Konger RL and Chan TC: Epidermal growth factor induces terminal differentiation in human epidermoid carcinoma cells. J Cell Physiol 156: 515-521, 1993.
70. Partik G, Hochegger K, Schorkhuber M and Marian B: Inhibition of epidermal-growth-factor-receptor-dependent signalling by tyrphostins A25 and AG1478 blocks growth and induces apoptosis in colorectal tumor cells in vitro. J Cancer Res Clin Oncol 125: 379-388, 1999.
71. Calonghi N, Pagnotta E, Parolin C, Mangano C, Bolognesi ML, Melchiorre C and Masotti L: A new EGFR inhibitor induces apoptosis in colon cancer cells. Biochem Biophys Res Commun 354: 409-413, 2007.
72. Marmor MD, Skaria KB and Yarden Y: Signal transduction and oncogenesis by ErbB/HER receptors. Int J Radiat Oncol Biol Phys 58: 903-913, 2004.
73. Engelman JA, Zhang XL, Razani B, Pestell RG and Lisanti MP: p42/44 MAP kinase-dependent and -independent signaling pathways regulate caveolin-1 gene expression. Activation of Ras-MAP kinase and protein kinase a signaling cascades transcriptionally down-regulates caveolin-1 promoter activity. J Biol Chem 274: 32333-32341, 1999.
74. Gardner OS, Shiau CW, Chen CS and Graves LM: Peroxisome proliferator-activated receptor γ-independent activation of p38 MAPK by thiazolidinediones involves calcium/calmodulin-dependent protein kinase II and protein kinase R: correlation with endoplasmic reticulum stress. J Biol Chem 280: 10109-10118, 2005.
75. Kim HP, Wang X, Nakao A, Kim SI, Murase N, Choi ME, Ryter SW and Choi AM: Caveolin-1 expression by means of p38beta mitogen-activated protein kinase mediates the antiproliferative effect of carbon monoxide. Proc Natl Acad Sci USA 102: 11319-11324, 2005.
76. Dasari A, Bartholomew JN, Volonte D and Galbiati F: Oxidative stress induces premature senescence by stimulating caveolin-1 gene transcription through p38 mitogen-activated protein kinase/Sp1-mediated activation of two GC-rich promoter elements. Cancer Res 66: 10805-10814, 2006.
77. Moriarty K, Kim KH and Bender JR: Estrogen receptor-mediated rapid signaling. Endocrinology 147: 5557-5563, 2006.
78. Chambliss KL, Simon L, Yuhanna IS, Mineo C and Shaul PW: Dissecting the basis of nongenomic activation of endothelial nitric oxide synthase by estradiol: role of ERalpha domains with known nuclear functions. Mol Endocrinol 19: 277-289, 2005.
79. Haynes MP, Li L, Sinha D, Russell KS, Hisamoto K, Baron R, Collinge M, Sessa WC and Bender JR: Src kinase mediates phosphatidylinositol 3-kinase/Akt-dependent rapid endothelial nitric-oxide synthase activation by estrogen. J Biol Chem 278: 2118-2123, 2003.
80. Song RX, Barnes CJ, Zhang Z, Bao Y, Kumar R and Santen RJ: The role of She and insulin-like growth factor 1 receptor in mediating the translocation of estrogen receptor alpha to the plasma membrane. Proc Natl Acad Sci USA 101: 2076-2081, 2004.
81. Kim SH, Yoo CI, Kim HT, Park JY, Kwon CH and Kim YK: Activation of peroxisome proliferator-activated receptor-γ (PPARγ) induces cell death through MAPK-dependent mechanism in osteoblastic cells. Toxicol Appl Pharmacol 215: 198-207, 2006.
82. Li M, Lee TW, Yim AP, Mok TS and Chen GG: Apoptosis induced by troglitazone is both peroxisome proliferator-activated receptor-γ- and ERK-dependent in human non-small lung cancer cells. J Cell Physiol 209: 428-438, 2006.
83. Klopotek A, Hirche F and Eder K: PPAR γ ligand troglitazone lowers cholesterol synthesis in HepG2 and Caco-2 cells via a reduced concentration of nuclear SREBP-2. Exp Biol Med 231: 1365-1372, 2006.
84. Bonofiglio D, Aquila S, Catalano S, Gabriele S, Belmonte M, Middea E, Qi H, Morelli C, Gentile M, Maggiolini M and Ando S: Peroxisome Proliferator-Activated Receptor (PPAR)γ activates p53 gene promoter binding to the NFKB sequence in human MCF7 breast cancer cells. Mol Endocrinol 20: 3083-3092, 2006.
85. Lavie Y, Fiucci G and Liscovitch M: Up-regulation of caveolae and caveolar constituents in multidrug-resistant cancer cells. J Biol Chem 273: 32380-32383, 1998.
86. Yang CP, Galbiati F, Volonte D, Horwitz SB and Lisanti MP: Upregulation of caveolin-1 and caveolae organelles in Taxol-resistant A549 cells. FEBS Lett 439: 368-372, 1998.
87. Belanger MM, Roussel E and Couet J: Up-regulation of caveolin expression by cytotoxic agents in drug-sensitive cancer cells. Anticancer Drugs 14: 281-287, 2003.
88. Garg TK and Chang JY: 15-deoxy-delta 12, 14-Prostaglandin J2 prevents reactive oxygen species generation and mitochondrial membrane depolarization induced by oxidative stress. BMC Pharmacol 4: 6, 2004.
89. Santucci L, Mencarelli A, Renga B, Pasut G, Veronese F, Zacheo A, Germani A and Fiorucci S, Nitric oxide modulates proapoptotic and antiapoptotic properties of chemotherapy agents: the case of NO-pegylated epirubicin. FASEB J 20: 765-767, 2006.
90. Cerutti PA: Prooxidant states and tumor promotion. Science 227: 375-381, 1985.
91. Burdon RH: Superoxide and hydrogen peroxide in relation to mammalian cell proliferation. Free Radic Biol Med 18: 775-794, 1995.
92. Pervaiz S, Ramalingam JK, Hirpara JL and Clement MV: Superoxide anion inhibits drug-induced tumor cell death. FEBS Lett 459: 343-348, 1999.
93. Ahmad KA, Clement MV, Hanif IM and Pervaiz S: Resveratrol inhibits drug-induced apoptosis in human leukemia cells by creating an intracellular milieu nonpermissive for death execution. Cancer Res 64: 1452-1459, 2004.
94. Panigrahy D, Shen LQ, Kieran MW and Kaipainen A: Therapeutic potential of thiazolidinediones as anticancer agents. Expert Opin Investig Drugs 12: 1925-1937, 2003.